FLCCC Responds to Wall Street Journal Article on Results of TOGETHER TRIAL
On March 18, 2022, The Wall Street Journal published an article entitled: ‘Ivermectin Didn’t Reduce Covid-19 Hospitalizations in Largest Trial to Date’.
The results of this trial, which was predetermined to show ivermectin as ineffective, aﬃrms the need for early treatment against COVID-19 and confirms that conflicted groups continue to influence competitor trials, ensuring they are designed to fail. Several organizations associated with the trial have a paid client relationship with Pfizer, which has secured Federal government contracts worth $5.3 billion for its antiviral treatment, Paxlovid. A full list of trial sponsors and associates can be found here.
It is therefore no surprise that the trial was designed to fail. In the medical community, it is common knowledge that COVID-19 becomes far more diﬃcult to treat the longer a patient has had symptoms. Treating early is imperative. Yet the TOGETHER trial studied patients where they started treatment up to eight days after the onset of symptoms.
Furthermore, no qualified physician or scientist recommends treating COVID-19 with the low dosage of ivermectin used in the trial, nor treating a patient with ivermectin for only three days on an empty stomach, as TOGETHER did. FLCCC physicians have understood for nearly 18 months that ivermectin works best against COVID-19 when administered with a fatty meal and until symptoms resolve.
Our frontline physicians – who were treating COVID-19 with corticosteroids months before the NIH recommended them – have found ivermectin is most effective as part of a treatment protocol that includes other FDA-approved medications and supplements backed by clinical and observational evidence. The use of our I-MASK+, MATH+ and I-RECOVER protocols have all been proven to be effective at corresponding stages of the illness.
Trials of generic medicines that are funded and influenced by profit-driven pharmaceutical companies will always fail. We need to create an independent, well-funded government body dedicated to conducting well-designed trials and transparent research studies of repurposed generic treatments – not only for COVID-19, but for all diseases that may have safe and affordable remedies. The use of independent research is our only hope of understanding how these medicines can best be used to help patients.